Highlights

Prolor Biotech Downgraded by Summer Street (PBTH)

 Source: ABMN Staff   |   Publish date: Mon, 12 Nov 2012, 11:58 AM   |    >> Read article in News website

Prolor Biotech (NASDAQ: PBTH) was downgraded by research analysts at Summer Street from a “buy” rating to a “sell” rating in a report released on Monday.

Prolor Biotech traded down 3.16% on Monday, hitting $4.60. Prolor Biotech has a 52-week low of $3.11 and a 52-week high of $6.69. The company’s market cap is $291.7 million.

Several other analysts have also recently commented on the stock. Analysts at Oppenheimer initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 29th. They set an “outperform” rating and a $7.00 price target on the stock. Analysts at Jefferies Group initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 22nd. They set a “buy” rating and a $8.00 price target on the stock.

Prolor Biotech, Inc. (Prolor), formerly Modigene Inc. is a development-stage biopharmaceutical company, utilizing technology to develop versions of therapeutic proteins.

Share this
Labels: PBTH, Analysts Downgrades, Market News

Related Stocks

Chart Stock Name Last Change Volume 

  Be the first to like this.
 


 

5109  2260  622  588 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 SPY 274.71+4.31 
 CHK 3.200.00 
 GE 14.49-0.13 
 BAC 32.03+0.34 
 QQQ 168.17+3.37 
 MU 46.53+2.28 
 HPE 18.14+1.73 
 EEM 49.72+0.87 
 XLF 29.12+0.43 
 UVXY 14.82-2.66 
Partners & Brokers